Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

diflorasone diacetate ointment

×

Overview

What is ApexiCon?

ApexiCon Ointment (diflorasone diacetate ointment USP 0.05%) contains 0.5 mg diflorasone diacetate in an ointment base.

Chemically, diflorasone diacetate is 6α,9-difluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21- diacetate with the molecular formula CHFO and a molecular weight of 494.54. The structural formula is represented below:

Each gram of ApexiCon Ointment (diflorasone diacetate ointment USP 0.05%), for topical administration, contains 0.5 mg diflorasone diacetate in an ointment base consisting of propylene glycol, glyceryl monostearate and white petrolatum.



What does ApexiCon look like?



What are the available doses of ApexiCon?

Sorry No records found.

What should I talk to my health care provider before I take ApexiCon?

Sorry No records found

How should I use ApexiCon?

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

ApexiCon Ointment (diflorasone diacetate ointment USP 0.05%) should be applied to the affected area as a thin film from one to three times daily depending on the severity or resistant nature of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated.


What interacts with ApexiCon?

Sorry No Records found


What are the warnings of ApexiCon?

Sorry No Records found


What are the precautions of ApexiCon?

Sorry No Records found


What are the side effects of ApexiCon?

Sorry No records found


What should I look out for while using ApexiCon?

Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.


What might happen if I take too much ApexiCon?

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See ).


How should I store and handle ApexiCon?

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP] .ApexiCon Ointment (diflorasone diacetate ointment USP 0.05%) is available in the following size tubes: Store at controlled room temperature 15° to 30°C (59° to 86°F). Keep tightly closed. January 2008PharmaDerm A division of Nycomed US Inc. Melville, NY 11747 www.pharmaderm.com I8394DR1/08 ApexiCon Ointment (diflorasone diacetate ointment USP 0.05%) is available in the following size tubes: Store at controlled room temperature 15° to 30°C (59° to 86°F). Keep tightly closed. January 2008PharmaDerm A division of Nycomed US Inc. Melville, NY 11747 www.pharmaderm.com I8394DR1/08 ApexiCon Ointment (diflorasone diacetate ointment USP 0.05%) is available in the following size tubes: Store at controlled room temperature 15° to 30°C (59° to 86°F). Keep tightly closed. January 2008PharmaDerm A division of Nycomed US Inc. Melville, NY 11747 www.pharmaderm.com I8394DR1/08 ApexiCon Ointment (diflorasone diacetate ointment USP 0.05%) is available in the following size tubes: Store at controlled room temperature 15° to 30°C (59° to 86°F). Keep tightly closed. January 2008PharmaDerm A division of Nycomed US Inc. Melville, NY 11747 www.pharmaderm.com I8394DR1/08 ApexiCon Ointment (diflorasone diacetate ointment USP 0.05%) is available in the following size tubes: Store at controlled room temperature 15° to 30°C (59° to 86°F). Keep tightly closed. January 2008PharmaDerm A division of Nycomed US Inc. Melville, NY 11747 www.pharmaderm.com I8394DR1/08


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Non-Clinical Toxicology
Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Drug Interactions:

General:

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulations tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See .)

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

The following local adverse reactions have been reported with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).